Geron (GERN) News Today

Renaissance Technologies LLC bought a new position in shares of Geron Co. (NASDAQ:GERN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 781,723 shares of the biopharmaceutical company's st

Darwin Global Management Ltd. bought a new stake in Geron Co. (NASDAQ:GERN - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 23,915,480 shares of the biopharmaceutical company's stock, va

Affinity Asset Advisors LLC reduced its position in Geron Co. (NASDAQ:GERN - Free Report) by 40.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,500,000 shares of the biopharmaceutical company's stock a

Farallon Capital Management LLC grew its holdings in Geron Co. (NASDAQ:GERN - Free Report) by 124.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,837,000 shares of the biopharmaceutical company's stock a

Rhumbline Advisers grew its position in Geron Co. (NASDAQ:GERN - Free Report) by 16.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 846,768 shares of the biopharmaceutical company's stock after buyi

Shares of Geron Co. (NASDAQ:GERN - Get Free Report) have been given a consensus rating of "Buy" by the nine brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigne

Geron (NASDAQ:GERN) Stock Price Up 7.1%

TD Asset Management Inc lifted its stake in shares of Geron Co. (NASDAQ:GERN - Free Report) by 403.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,201,200 shares of the biopharmaceutical company's stock after buying an additional 962,

Geron Co. (NASDAQ:GERN - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2024 EPS estimates for Geron in a research report issued on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the biopharmaceutical company will post earnings per share of ($0.09) for

Bank of New York Mellon Corp increased its stake in Geron Co. (NASDAQ:GERN - Free Report) by 26.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,016,622 shares of the biopharmaceutical company's stock after buying an addi

Geron (NASDAQ:GERN) Shares Up 6.1%

Leerink Partners initiated coverage on shares of Geron in a research report on Monday. They issued an "outperform" rating and a $7.00 price objective for the company.

Geron (NASDAQ:GERN) Trading Down 7.6%

Geron (NASDAQ:GERN) Trading 2.6% Higher

Shares of Geron Co. (NASDAQ:GERN - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to

Geron (NASDAQ:GERN) Stock Price Up 3.6%

Hennion & Walsh Asset Management Inc. acquired a new stake in Geron Co. (NASDAQ:GERN - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 253,857 shares of the biopharmaceutical company's stock, valued at approximately $1,076,

Geron Co. (NASDAQ:GERN - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 57,860,000 shares, a growth of 29.6% from the July 15th total of 44,660,000 shares. Based on an average daily volume of 11,800,000 shares, the short-interest ratio is currently 4.9 days.

Geron Co. (NASDAQ:GERN - Free Report) - Equities research analysts at Wedbush upped their Q3 2024 earnings estimates for Geron in a report released on Thursday, August 8th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will post earnings per share of ($0.08) for the q

Geron (NASDAQ:GERN - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.88 million for the quarter, compared to analyst estimates of $0.34 million. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The company's revenue for the quarter was up 2941.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.09) earnings per share.

Geron Co. (NASDAQ:GERN - Free Report) - Research analysts at Wedbush increased their FY2028 earnings estimates for shares of Geron in a research note issued to investors on Thursday, August 8th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will earn $0.78 per share f

Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Geron in a report on Thursday.

StockNews.com raised shares of Geron to a "sell" rating in a report on Monday.